Early trial tests new weapons against hidden HIV

NCT ID NCT07217379

Recruiting now Disease control Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing the safety of two new antibody drugs, MGD014 and MGD020, in people with HIV who are on stable medication. Researchers want to see if these antibodies, sometimes given with another drug to 'wake up' hidden virus, are well-tolerated. The study will also check how long the antibodies stay in the body and their effect on inactive HIV.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV (HUMAN IMMUNODEFICIENCY VIRUS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Kenya Medical Research Institute/Walter Reed Project
NOT_YET_RECRUITING

Kericho, Kenya

Contact
Moi University Clinical Research Center
NOT_YET_RECRUITING

Eldoret, Kenya

Contact
University of North Carolina
RECRUITING

Chapel Hill, North Carolina, 27514, United States

Contact

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

HIV (HUMAN IMMUNODEFICIENCY VIRUS)